olfactory receptor family 6 subfamily B member 3Genealiases: OR6B3P · OR6B3Q
Q-omics provides the consensus-scored OR6B3 profile across patient tissues and cancer cell-line models. OR6B3 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in DLBC. Among the 18 cancer types available for tumor–normal comparison, OR6B3 is differentially expressed in 1, with the highest sampling consensus in KIRP. Additionally, OR6B3 RNA expression shows 6,444 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight DLBC, KIRP, and STAD as cancer lineages where OR6B3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OR6B3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OR6B3 survival associations across molecular data types. OR6B3 RNA expression shows survival associations in the most cancer types (13), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OR6B3 RNA expression–survival associations across cancer types. High OR6B3 expression shows unfavorable associations in DLBC, ACC, LIHC, ESCA and UCS, but favorable associations in BRCA. The DLBC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .010). Together, the overview and detailed table identify DLBC as the clearest survival context for OR6B3 RNA expression.
This table summarizes OR6B3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for OR6B3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OR6B3 shows higher tumor expression in KIRP. The KIRP box plot shows higher OR6B3 RNA expression in tumor versus normal tissue (log2 FC = +0.007, t-test p = .040).
This table shows molecular features associated with OR6B3 in patient tissues and cancer cell lines. In patient samples, OR6B3 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, OR6B3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and KIDNEY.
